Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kent G Krejci

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Current Urology Reports|January 23, 2003
Should there be a size limit for elective nephron-sparing surgery?Kent G Krejci, Bradley C Leibovich
The Journal of Urology|January 10, 2004
Immunotherapy for urological malignanciesKent G Krejci, Mary A Markiewicz, Eugene D Kwon
Urology|October 11, 2003
Nephron-sparing surgery for renal cell carcinoma: clinicopathologic features predictive of patient outcomeKent G Krejci, Michael L Blute, John C Cheville, et al.
Human Vaccines & Immunotherapeutics|December 16, 2020
Safety and immunogenicity of an adjuvanted <i>Escherichia coli</i> adhesin vaccine in healthy women with and without histories of recurrent urinary tract infections: results from a first-in-human phase 1 studyGary R Eldridge, Heidi Hughey, Lois Rosenberger, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 2004
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic targetR Houston Thompson, Michael D Gillett, John C Cheville, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Current Urology Reports|January 23, 2003
Should there be a size limit for elective nephron-sparing surgery?Kent G Krejci, Bradley C Leibovich
The Journal of Urology|January 10, 2004
Immunotherapy for urological malignanciesKent G Krejci, Mary A Markiewicz, Eugene D Kwon
Urology|October 11, 2003
Nephron-sparing surgery for renal cell carcinoma: clinicopathologic features predictive of patient outcomeKent G Krejci, Michael L Blute, John C Cheville, et al.
Human Vaccines & Immunotherapeutics|December 16, 2020
Safety and immunogenicity of an adjuvanted <i>Escherichia coli</i> adhesin vaccine in healthy women with and without histories of recurrent urinary tract infections: results from a first-in-human phase 1 studyGary R Eldridge, Heidi Hughey, Lois Rosenberger, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 2004
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic targetR Houston Thompson, Michael D Gillett, John C Cheville, et al.
Pageof 1